Search Results - immunotherapy

127 Results Sort By:
Neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and neurodegenerative disorders
NU 2025-113 (NU 2016-137, NU 2018-176, NU 2019-179, NU 2023-007, NU 2024-250, NU 2025-038) INVENTORS Richard Silverman (Weinberg College of Arts and Sciences, Department of Chemistry) SHORT DESCRIPTION Novel highly selective neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and other cancers with high expression...
Published: 4/1/2026   |   Updated: 4/1/2026   |   Inventor(s):  
Keywords(s): ALS - Amyotrophic Lateral Sclerosis, AUTM26C1, BIAUTM1, Cancer/Oncology, Cardiology and Cardiovascular disease, Immunodeficiency, Immunology, Immunotherapy, Melanoma, Neurodegenerative disease, Neuroinflammation, nNOS, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Anticancer IgG Against Multiple Epitopes on Live Tumors Upon Disruption of ‘Self’ Signaling by CD47
A method to combine two or three monoclonal antibodies (mABs) into one treatment to successfully bind to multiple cancer cell surface epitopes and promote targeted degradation by phagocytosis. Problem: Phagocytosis of ‘self’ cells is generally inhibited by a key macrophage checkpoint interaction between SIRPα on the macrophage and...
Published: 12/15/2025   |   Updated: 12/15/2025   |   Inventor(s): Dennis Discher, Jason Andrechak, Lawrence Dooling
Keywords(s): Antibody, Bioengineering, Cell Therapy, Drug Target, Immunology, Immunoncology, Immunotherapy, Oncology, Platform Technology
Category(s): Technology Classifications > Therapeutics
The use of complex or fusion protein of soluble MIC (Smic) and antibody to treat MIC-negative cancer
NU 2019-146 INVENTORS Jennifer Wu* SHORT DESCRIPTION A fusion protein complex comprising soluble MIC and a non-blocking sMIC-neutralizing antibody that effectively activates CD8 T cells for the treatment of MIC-negative cancer. BACKGROUND Effective T cell co-stimulation is critical for durable tumor control, yet many current immunotherapies...
Published: 4/9/2026   |   Updated: 12/3/2025   |   Inventor(s):  
Keywords(s): Antibody, Biologic, Cancer/Oncology, Immunotherapy, Infectious disease, Research tool, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Engineered B-cell Therapy for Cancer Treatment
NU 2022-218 INVENTORS Catalina Lee Chang* Maciej Lesniak* SHORT DESCRIPTION Engineered B cells with reduced expression of key immune checkpoint proteins designed to boost cancer immunotherapy efficacy. BACKGROUND Immunotherapy has transformed cancer treatment; however, its application to brain tumors remains limited by the immunosuppressive...
Published: 4/8/2026   |   Updated: 12/3/2025   |   Inventor(s):  
Keywords(s): Cancer/Oncology, Cell therapy, Immunotherapy, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Small Molecule Inhibitors Targeting OTUD4-CD73 Interaction for Immune-Cold Tumors
Application This technology introduces small molecule inhibitors, ST80 and Z22, to disrupt the protein-protein interaction (PPI) between OTUD4 and CD73. These inhibitors enhance tumor immunogenicity by reducing CD73 stabilization, improving the immune response in triple-negative breast cancer (TNBC) and other immune-cold tumors. Key Benefits ST80...
Published: 4/10/2026   |   Updated: 11/13/2025   |   Inventor(s): Yong Wan, Yueming Zhu, Ivet Bahar, Anupam Banerjee, Jiyoung Lee
Keywords(s): Drug Target Identification, Immunotherapy, Oncology Treatments, Small Molecule, Therapeutics
Category(s): TechPub Algolia > Drug Discovery
Protein Polymers for Organelle Engineering
Application Protein polymers enabling engineering of human membraneless organelles. Key Benefits Versatile applications across immunotherapy, cell therapy, and other therapeutic modalities. High biocompatibility with minimal reactivity with endogenous molecules. Deployable for organelle-level functionalization of human cells. Market Summary Proteins...
Published: 3/10/2026   |   Updated: 11/7/2025   |   Inventor(s): Felipe Quiroz, Ian Sicher, Spencer Hayes, Maria Giraldo-Castaño, Mariell Pascual, Alexa Avecilla
Keywords(s): Biomaterials, Cell Therapy, Immunotherapy, Protein and Peptide Therapeutics, Regenerative Medicine, Research Tools
Category(s): TechPub Algolia > Therapeutics
T Cells Targeting Misformed Proteins to Treat Neurodegenerative and Muscular Diseases
Antigen-specific immunotherapy with engineered cytotoxic T cells targeting misformed proteins to treat neurodegenerative and muscular diseases. Problem: Neurodegenerative and muscular diseases, such as amyotrophic lateral sclerosis (ALS), inclusion body myositis (IBM), and Alzheimer’s disease (AD), collectively affect over 5 million adults...
Published: 11/11/2025   |   Updated: 10/30/2025   |   Inventor(s): Ning Jenny Jiang, Shahab Chizari
Keywords(s): Bioengineering, Cell Therapy, Immunology, Immunotherapy, Inflammation, Neurodegenerative Diseases
Category(s): Technology Classifications > Diagnostics, Technology Classifications > Research Tools & Reagents, Technology Classifications > Therapeutics
TYRP-1 Chimeric Antigen Receptor to Treat Melanoma (UCLA Case No. 2020-106)
UCLA researchers in the Departments of Surgical Oncology and Microbiology, Immunology, & Molecular Genetics. have developed a CAR-T therapy that targets TYRP-1 for the treatment of melanoma. BACKGROUND: Immune checkpoint blockade (ICB) is a rapidly emerging immunotherapy approach that uses patients’ immune cells to treat cancer. In contrast...
Published: 1/13/2026   |   Updated: 9/15/2025   |   Inventor(s): Cristina Puig Saus, Antoni Ribas, Yvonne Chen
Keywords(s): Gene Therapy, Hematology, Immunotherapy, Research Methods
Category(s): Therapeutics > Hematology
Delivery of sustained local and systemic immunomodulation
Reducing treatment burden with continuous immune activation Background: Current immunotherapy approaches face significant limitations in both delivery and patient experience. Standard treatments rely on either systemic intravenous injections of antibodies or small molecules that require frequent clinic visits, or localized injections that provide...
Published: 4/2/2026   |   Updated: 6/13/2025   |   Inventor(s): Srinivas Sridhar, Needa Brown, Jennifer Guerriero, Alexander Gottlieb
Keywords(s): biocompatible, Biodegradable, Biomaterials, Cancer, Drug Delivery, Immunoengineering, immunotherapy, implant, Nanomedicine
Category(s): Technology Classifications > 1. Life Science > Therapeutics
Modified Hyaluronic Acid Hydrogels Containing Hyaluronidase for the Time‐Controlled and Targeted Release of anti-CTLA-4 and other Therapeutic Antibodies (UCLA Case No. 2016-526)
UCLA researchers from the Department of Medicine have developed a novel therapeutic platform for the administration of low-dose Cytotoxic T-lymphocyte Associated Protein 4 (CTLA-4) antibody for cancer immunotherapy that synergizes with conventional PD-1 therapy while sparing systemic autoimmune toxicity. BACKGROUND: Immune checkpoint inhibitor (CPI)...
Published: 7/17/2025   |   Updated: 5/30/2025   |   Inventor(s): Michael Roth, Airi Harui
Keywords(s): Cancer Immunotherapy, Immunotherapy
Category(s): Platforms > Drug Delivery, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology
1 2 3 4 5 6 7 8 9 10 ...